Industry

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

– CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients – Durable responses seen in both solid tumors and hematologic malignancies in the dose escalation with a 44% disease control rate in the response-evaluable population – Safety and clinical activity from the Phase 1 … [Read more…]

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2-Low Metastatic Breast Cancer with HR-Positive and HR-Negative Disease

AstraZeneca and Daiichi Sankyo’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary endpoint of progression-free survival in patients with HR-positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy ENHERTU is the first HER2-directed therapy to … [Read more…]

Foundation Medicine Announces Strategic Collaboration with Arvinas

Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein Degrader CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASCO22–Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne®Liquid CDx as a companion diagnostic for use with Arvinas’ bavdegalutamide … [Read more…]

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

New research from Gelesis highlights ongoing stigmatization of people with obesity and diabetes BOSTON–(BUSINESS WIRE)–Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new findings about the role of language in obesity and diabetes scientific literature at the American Diabetes Association’s annual conference. The study sought to understand the extent to which person-first … [Read more…]

Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial

KEYNOTE-716 is the first Phase 3 trial with an anti-PD-1/L1 to significantly improve distant metastasis-free survival (DMFS) and recurrence-free survival (RFS) for these patients Based on KEYNOTE-716, KEYTRUDA received US FDA approval and a positive EU CHMP opinion for the adjuvant treatment of patients aged 12 and older with completely resected stage IIB and IIC … [Read more…]

ENHERTU® Reduced the Risk of Disease Progression or Death by 50% vs. Chemotherapy in Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Daiichi Sankyo and AstraZeneca’s ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary endpoint of progression free survival in patients with HR positive disease, reducing the risk of disease progression or death by 49% vs. chemotherapy ENHERTU is the first HER2 … [Read more…]

Creatv Bio’s LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days

Results to be presented at ASCO 2022 Annual Meeting in Chicago, IL ROCKVILLE, Md.–(BUSINESS WIRE)–Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response of metastatic breast cancer (mBC) to new lines of therapy following a single cycle of therapy … [Read more…]

AHF Swiftly Brings Aid to Recife, Brazil

In the northeast state of Pernambuco, over 100 people have died due to torrential rains and flooding AHF Brazil, which provides HIV/AIDS care in 25 clinics in the country—including 3 clinics in Pernambuco and 5 in Recife—is delivering humanitarian aid to help over 600 individuals and families SÃO PAULO–(BUSINESS WIRE)–Following torrential rains and flooding that … [Read more…]

Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma

— In Three-Year Follow-up in Relapsed/Refractory Mantle Cell Lymphoma, Tecartus Induced High Rates of Durable Response (ORR 91%, 68% CR) and a Median Overall Survival of 46.6 Months — — In Two-Year Follow-up in Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Tecartus Induced High Rates of Durable Response (CR+CRi 73.1%) and a Median Overall Survival … [Read more…]

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – 83% Reported Grade 3 Adverse Events of Special … [Read more…]